The Billion-Dollar Glue: How AI and Novartis Are Backing a Drug Revolution

BOSTON, MA – June 10, 2026 – In a move that signals a seismic shift in pharmaceutical innovation, global giant Novartis has deepened its partnership with Orionis Biosciences, committing up to $1.4 billion to harness a revolutionary class of drugs known as “molecular glues.” This expanded collaboration isn't just another big-pharma deal; it’s a high-stakes bet on the power of artificial intelligence to solve one of drug discovery's most persistent challenges: hitting targets that were once considered “undruggable.”

The agreement provides Orionis, a clinical-stage life sciences company with roots in Boston and Ghent, Belgium, with a $40 million upfront payment to advance its work. The collaboration will leverage Orionis’s proprietary Allo-Glue™ platform to discover and design novel medicines across multiple disease areas. For decades, the discovery of molecular glues has been largely a matter of serendipity. Now, this partnership aims to transform that luck-based process into a systematic, predictable, and scalable science, potentially unlocking a new arsenal of therapies for some of our most intractable diseases.

Sticking It to Disease: The Science of Molecular Glues

For most of modern medicine, drugs have worked like keys fitting into locks. A small molecule is designed to bind to a specific pocket on a disease-causing protein, blocking its function. The problem? It’s estimated that over 85% of the proteins in the human body lack these well-defined “locks,” rendering them effectively undruggable by conventional means. This vast, untapped landscape of disease targets includes many of the master-switch proteins that drive cancers and neurodegenerative disorders.

Molecular glues operate on a completely different principle. Instead of blocking a protein, these small molecules act as microscopic matchmakers. They induce or stabilize an interaction between two proteins that wouldn't normally stick together. In the most promising application, a glue molecule coaxes a target protein into close proximity with an E3 ubiquitin ligase—a key component of the cell’s natural garbage disposal system. This induced proximity tags the harmful protein for destruction by the proteasome. A single glue molecule can catalytically trigger the elimination of many target proteins, making the approach highly efficient at low doses.

“The therapeutic potential is immense,” notes one academic researcher not involved in the deal. “You're not just inhibiting a target; you're removing it from the equation entirely. This could overcome drug resistance and address the root causes of diseases in a way we couldn't before.”

Despite this promise, finding these glues has been notoriously difficult. The most famous examples, like the immunomodulatory drugs (IMiDs) used to treat multiple myeloma, were discovered by chance, their true mechanism only understood years later. The complexity of orchestrating a three-body interaction (glue, target, and ligase) has made rational design a formidable challenge, until now.

From Serendipity to Strategy: The AI-Powered Platform

This is where Orionis Biosciences enters the picture. The company has spent years building a platform designed to industrialize molecular glue discovery. Its Allo-Glue™ technology moves beyond one-off screening, enabling a genome-scale interrogation of the entire human proteome against vast chemical libraries to systematically map out productive interactions.

At the heart of this engine is a powerful fusion of artificial intelligence and robotic automation. As Riccardo Sabatini, Chief Data Scientist at Orionis, explained, these advances have transformed the process. “Our recent advances in AI and robotic automation have accelerated all aspects of molecular glue discovery, from systematic prioritization of productive target–ligase pairs to glue candidate discovery and optimization,” he stated. The platform sifts through an astronomical number of potential combinations, using machine learning models trained on over 150 million previously mapped molecular interactions to predict which pairings are most likely to yield a therapeutic effect. “This is exactly the kind of platform maturity that makes collaborations like this possible,” Sabatini added.

By turning a serendipitous art into a data-driven science, Orionis aims to rapidly identify and refine glue candidates for specific, high-value targets chosen by Novartis, dramatically shortening the discovery timeline and increasing the probability of success.

A Billion-Dollar Vote of Confidence

The financial terms of the deal underscore the significance of this technological leap. While the $40 million upfront payment provides Orionis with immediate non-dilutive funding, the potential $1.4 billion in research, development, and commercial milestones represents a powerful validation of its platform. This structure is common for platform technology deals, but its scale places it in the upper echelon, signaling Novartis’s deep conviction in the approach.

“Having such a partner continue to engage deeply with us is a strong validation of the value of our molecular glue platform and the progress we have achieved,” said Niko Kley, Chief Executive Officer of Orionis Biosciences. This expanded deal builds on an existing relationship, suggesting that Orionis’s technology has already delivered promising results.

For Novartis, the collaboration is a strategic move to stay at the forefront of innovation. Large pharmaceutical companies are increasingly looking to agile biotechs for next-generation therapeutic modalities. John Tallarico, Head of Discovery Sciences at Novartis, framed the partnership as a way to push the boundaries of medicine. “We are excited to deepen our collaboration with Orionis and to explore the full potential of molecular glue modalities,” he said. “The Orionis platform offers an opportunity to rapidly uncover and design molecular glue mechanisms, enabling us to expand the horizon of targetable biology for future therapies.”

The move also situates Novartis prominently within a competitive and burgeoning field. Other major players, including Genentech—which also has a partnership with Orionis—Amgen, and a host of well-funded startups are all racing to claim a stake in the induced proximity space.

Unlocking a New Frontier for Patients

Beyond the corporate strategy and technological marvels, the ultimate promise of this collaboration lies in its potential impact on human health. The “undruggable” targets that molecular glues can address are implicated in some of the most challenging diseases, including aggressive cancers driven by rogue transcription factors and neurodegenerative conditions caused by toxic protein buildups.

By providing a tool to systematically drug this previously inaccessible part of the proteome, the Orionis-Novartis partnership could pave the way for entirely new treatment paradigms. It represents a shift from merely managing symptoms to targeting the core drivers of disease at a fundamental level. While the path from a discovery platform to an approved medicine is long and fraught with risk, this billion-dollar handshake represents a significant step forward. It is a clear signal that the future of drug discovery may be less about finding a key for a lock and more about finding the right glue to re-engineer cellular machinery for our own benefit.